67 citations
,
October 2005 in “Annals of Oncology” This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
6 citations
,
November 2007 in “British Journal of Dermatology” This study found that topical fulvestrant did not significantly improve hair growth parameters in men and postmenopausal women with androgenetic alopecia, unlike minoxidil, which was more effective in men.
11 citations
,
January 2007 in “Veterinary dermatology” This study found that administerating 10 mg/kg intramuscular fulvestrant did not stimulate hair regrowth in Pomeranian dogs with alopecia X, though higher doses may warrant further investigation.
June 2026 in “Journal of cancer research updates” This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.